摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-debenzoyl-2-(3-azidobenzoyl)-10-propanoyl-3'-dephenyl-3'-trifluoromethyldocetaxel | 740802-73-7

中文名称
——
中文别名
——
英文名称
2-debenzoyl-2-(3-azidobenzoyl)-10-propanoyl-3'-dephenyl-3'-trifluoromethyldocetaxel
英文别名
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-12-propanoyloxy-15-[(2R,3R)-4,4,4-trifluoro-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]oxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] 3-azidobenzoate
2-debenzoyl-2-(3-azidobenzoyl)-10-propanoyl-3'-dephenyl-3'-trifluoromethyldocetaxel化学式
CAS
740802-73-7
化学式
C41H51F3N4O15
mdl
——
分子量
896.869
InChiKey
RRPNTSZWLFTVMC-NTOLQMFISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    63
  • 可旋转键数:
    16
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.66
  • 拓扑面积:
    245
  • 氢给体数:
    4
  • 氢受体数:
    20

反应信息

  • 作为产物:
    描述:
    [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-12-propanoyloxy-9-triethylsilyloxy-15-[(2R,3R)-4,4,4-trifluoro-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-tri(propan-2-yl)silyloxybutanoyl]oxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] 3-azidobenzoate 在 pyridine hydrofluoride 作用下, 以 吡啶乙腈 为溶剂, 生成 2-debenzoyl-2-(3-azidobenzoyl)-10-propanoyl-3'-dephenyl-3'-trifluoromethyldocetaxel
    参考文献:
    名称:
    Syntheses and structure–activity relationships of novel 3′-difluoromethyl and 3′-trifluoromethyl-taxoids
    摘要:
    A series of novel 3'-difluoromethyl-taxoids and 3'-trifluoromethyl-taxoids with modifications at the C2 and C10 positions were synthesized and evaluated for their in vitro cytotoxicities against human breast carcinoma (MCF7-S, MCF7-R, LCC6-WT, LCC6-MDR), non-small cell lung carcinoma (H460) and colon adenocarcinoma (HT-29) cell lines. These second-generation fluoro-taxoids exhibited several times to more than 20 times better potency than paclitaxel against drug-sensitive cancer cell lines, MCF7-S, LCC6-WT. H460, and HT-29. These fluoro-taxoids also possess two orders of magnitude higher potency than paclitaxel against drug-resistant cancer cell lines, MCF7-R and LCC6-MDR. Structure-activity relationship study shows the importance of the C10 modification for increasing the activity against multidrug-resistant cancer cell lines. Effects of the C2-benzoate modifications on the potency in the 3'-difluoromethyl-taxoid series are very clear- (i.e., F < MeO < Cl < N-3), while those in the 3'-trifluoromethyl-taxoid series are less obvious. Also, different trends in the sensitivity to the C2-substitution are observed between drug-sensitive cell lines and drug-resistant cancer cell lines that overexpress efflux pumps. (c) 2008 Elsevier B.V. All rights reserved.
    DOI:
    10.1016/j.jfluchem.2008.05.013
点击查看最新优质反应信息